Ipsen Biopharmaceuticals
Ipsen Biopharmaceuticals, Inc.
One Main Street,
Cambridge, MA 02142
Phone: (617) 679-5600Website: https://www.ipsen.com/us/Careers: www.ipsen.com/us/careers
Latest news
- Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
13 February 2024 - FDA Approves Sohonos (palovarotene) for the Treatment of Fibrodysplasia Ossificans Progressiva
16 August 2023 - FDA Approves Bylvay for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome
13 June 2023 - Ipsen Receives Complete Response Letter for Palovarotene, an Investigational Treatment for Fibrodysplasia Ossificans Progressiva
23 December 2022 - Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
29 June 2022 - Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Resubmit Following Additional Data Analyses
13 August 2021 - FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
20 July 2021 - Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
28 May 2021 - Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
25 January 2021 - Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
8 December 2020
Drugs Associated with Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. manufactures, markets and/or distributes more than 7 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Bylvay
Generic name: odevixibat Drug class: miscellaneous GI agents |
||
|
Dysport
Generic name: abobotulinumtoxinA Drug class: skeletal muscle relaxants |
9 reviews | 4.7 / 10 |
|
Increlex
Generic name: mecasermin Drug class: insulin-like growth factors |
||
|
Onivyde
Generic name: irinotecan liposomal Drug class: miscellaneous antineoplastics |
||
|
Sohonos
Generic name: palovarotene Drug class: miscellaneous uncategorized agents |
||
|
Somatuline Depot
Generic name: lanreotide Drug class: somatostatin and somatostatin analogs |
1 review | 8.0 / 10 |
|
Tazverik
Generic name: tazemetostat Drug class: miscellaneous antineoplastics |
1 review | 9.0 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
